HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Sonodynamic therapy decreased neointimal hyperplasia after stenting in the rabbit iliac artery.

AbstractBACKGROUND:
In-stent restenosis remains a pivotal problem after coronary and peripheral stenting. Sonodynamic therapy inhibits tumor growth by means of cytotoxicity after the activation of sonochemical sensitizers by ultrasound. PAD-S31 is known to be a water-soluble, chlorin-derivative sonochemical sensitizer. We assessed the efficacy of sonodynamic therapy using this sensitizer on neointimal hyperplasia in a rabbit stent model.
METHODS AND RESULTS:
Stents were implanted in the iliac arteries of 16 rabbits. A total of 32 stented arteries were randomized to sonodynamic therapy, control, ultrasound exposure, and PAD-S31 groups. One hour after the intravenous administration of PAD-S31 (25 mg/kg body weight), ultrasound energy (1 MHz, 0.3 W/cm(2)) was delivered transdermally to the sonodynamic therapy group. At 28 days, all stent sites were analyzed morphometrically. The size of the intimal cross-sectional area was smaller in the sonodynamic therapy group than in the control, ultrasound, and PAD-S31 groups (0.31+/-0.07 versus 1.38+/-0.47, 1.66+/-0.71, and 1.61+/-0.42 mm(2), respectively; P<0.05). The ratio of the intimal and medial cross-sectional area was smaller in the sonodynamic therapy group than in the control, ultrasound, and PAD-S31 groups (0.71+/-0.22 versus 2.53+/-1.39, 2.48+/-0.60, and 3.45+/-1.42 mm(2); P<0.05).
CONCLUSIONS:
Sonodynamic therapy with PAD-S31 is considered to be a feasible treatment modality for noninvasively inhibiting neointimal hyperplasia in a rabbit iliac stent model.
AuthorsKoh Arakawa, Kousukue Hagisawa, Hiroyuki Kusano, Satoru Yoneyama, Akira Kurita, Tsunenori Arai, Makoto Kikuchi, Isao Sakata, Shin-ichirou Umenura Si, Fumitaka Ohsuzu
JournalCirculation (Circulation) Vol. 105 Issue 2 Pg. 149-51 (Jan 15 2002) ISSN: 1524-4539 [Electronic] United States
PMID11790692 (Publication Type: Evaluation Study, Journal Article)
Chemical References
  • 13,17-bis(1-carboxypropionyl)carbamoylethyl-3-ethenyl-8-ethoxyiminoethylidene-7-hydroxy-2,7,12,18-tetramethyl porphyrin
  • Porphyrins
Topics
  • Animals
  • Combined Modality Therapy
  • Graft Occlusion, Vascular (etiology, pathology, therapy)
  • Hyperplasia (etiology, pathology, therapy)
  • Iliac Artery (pathology)
  • Porphyrins (therapeutic use)
  • Rabbits
  • Stents (adverse effects)
  • Ultrasonic Therapy (methods)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: